

**CONFERENCE PROGRAM**

8:00 am - 9:00 am	Registration and Continental Breakfast
9:00 am - 9:05 am	<p style="text-align: center;"><b>Welcome</b> Susan Marlin, Executive Director, Clinical Trials Ontario</p>
9:05 - - 9:10 am	<p style="text-align: center;"><b>Opening Remarks</b> Karen Michell, Executive Director, Council of Academic Hospitals of Ontario</p>
9:15 am - 10:45 am	<p><b><u>SESSION 1: EVOLVING CHALLENGES AND OPPORTUNITIES FOR CLINICAL TRIALS</u></b></p> <p>Session Moderator: <b>Raphael Hofstein</b>, President and CEO, MaRS Innovation; CTO Board Member</p> <p><b>Keynote Address: Challenges and Opportunities For Clinical Trials</b></p> <ul style="list-style-type: none"> <li>• <b>Kenneth A. Getz</b>, Director, Sponsored Research Programs, Tufts Center for the Study of Drug Development; Chairman and Founder, The Center for Information and Study on Clinical Research Participation</li> </ul> <p><b>Panel: Current challenges and opportunities associated with clinical trials, as well as the evolution of clinical trials</b></p> <ul style="list-style-type: none"> <li>• <b>Nita Arora</b>, Regional Head, Affiliate Management, North America - Hoffmann La Roche</li> <li>• <b>Neil Maresky</b>, Vice President, Scientific Affairs, AstraZeneca Canada</li> <li>• <b>James Wilson</b>, President, Brancorth Medical Inc.; CTO Board Member</li> <li>• Moderator: <b>Paul Lucas</b>, President and Chair, Life Sciences Ontario</li> </ul>
10:45 am - 11:00 am	Coffee Break
11:00 am - 12:30 pm	<p><b><u>SESSION 2: DEVELOPMENTS IN THE CLINICAL TRIALS ENVIRONMENT: CANADA AND ONTARIO</u></b></p> <p>Session Moderator: <b>Clive Ward-Able</b>, Executive Director, R&amp;D, Amgen; CTO Board Member</p> <p><b><u>National Updates</u></b></p> <p><b>Canada's Research-based Pharmaceutical Companies (Rx&amp;D)</b></p> <ul style="list-style-type: none"> <li>• <b>Jared Rhines</b>, Vice President, Scientific and Strategic Affairs, Rx&amp;D</li> </ul> <p><b>Newly-Merged Association of Canadian Academic Healthcare Organizations/Canadian Healthcare Association (ACAHO-CHA)</b></p> <ul style="list-style-type: none"> <li>• <b>Tina Saryeddine</b>, Assistant Vice President Research &amp; Policy Analysis, ACAHO-CHA</li> </ul> <p><b>Strategy for Patient-Oriented Research (SPOR) - Streamlining Health Research Ethics Review (SHRER) Committee</b></p> <ul style="list-style-type: none"> <li>• <b>Sharon Freitag</b>, Director, Research Ethics Office, St. Michael's Hospital; Chair, SHRER Committee</li> </ul> <p><b>Network of Networks (N2) and Canadian Cancer Clinical Trials Network (3CTN)</b></p> <ul style="list-style-type: none"> <li>• <b>Karen Arts</b>, Director of Business Development, High Impact Clinical Trials Program, Ontario Institute for Cancer Research (OICR); Board Chair, N2; Director of External Initiatives, 3CTN</li> </ul> <p><b>Canadian Association for Independent Clinical Research (CAICR)</b></p> <ul style="list-style-type: none"> <li>• <b>Jack Corman</b>, President, IRB Services; President, CAICR</li> </ul>

	<p><b><u>Ontario Update</u></b></p> <p><b>Clinical Trials Ontario</b></p> <ul style="list-style-type: none"> <li>• Susan Marlin, Executive Director, Clinical Trials Ontario</li> </ul> <p><b>Liability Insurance for Research: No Insurance, Traditional Insurance, Self- Insurance, or Captive Insurance?</b></p> <ul style="list-style-type: none"> <li>• Frank Naus, Director of Research Administration, Hamilton Health Sciences Corporation</li> </ul>
12:30 pm - 1:30 pm	Lunch
1:30 pm - 2:45 pm	<p><b><u>SESSION 3: CHALLENGES AND OPPORTUNITIES IN STREAMLINING RESEARCH ETHICS REVIEW</u></b></p> <p>Session Moderator: <b>Raphael Saginur</b>, Chair, Ottawa Health Science Network REB; CTO Board Member</p> <p><b>An investigator’s experience in obtaining Research Ethics Board (REB) Approval</b></p> <ul style="list-style-type: none"> <li>• Laurie Morrison, Professor and Clinician Scientist, Division of Emergency Medicine, Department of Medicine, University of Toronto and Li Ka Shing Knowledge Institute, St. Michael’s Hospital</li> </ul> <p><b>CTO REB Qualification Process</b></p> <ul style="list-style-type: none"> <li>• Anita Sengar, Manager, Operations, University Health Network Research Ethics Board</li> </ul> <p><b>Preparing for a Streamlined Ethics Review System in Ontario</b></p> <p><b>Lessons Learned: UK National Research Ethics Service, US Central Institutional Review Board and the Ontario Cancer Research Ethics Board</b></p> <ul style="list-style-type: none"> <li>• Janet Manzo, Executive Director, Ontario Cancer Research Ethics Board (OCREB)</li> </ul> <p><b>Panel: Challenges and Opportunities from an REB Perspective</b></p> <ul style="list-style-type: none"> <li>• Michael Coughlin, Chair, Tri-Hospital Research Ethics Board</li> <li>• Sharon Freitag, Director, Research Ethics Office, St. Michael’s Hospital</li> <li>• Jack Holland, Oncology REB Review Panel Chair, University Health Network</li> <li>• David Mazer, Chair, Research Ethics Board, St. Michael’s Hospital</li> <li>• Keitha McMurray, Director, Human Research Protections Program, Sunnybrook Health Sciences Centre</li> <li>• Moderator: Janet Manzo, Executive Director, Ontario Cancer Research Ethics Board (OCREB)</li> </ul>
2:45 pm - 3:00 pm	Coffee Break
3:00 pm - 4:45 pm	<p><b><u>SESSION 4: CLINICAL TRIALS PARTICIPANT ENGAGEMENT AND RETENTION</u></b></p> <p>Session Moderator: <b>Michael Wood</b>, Professor Northern Ontario School of Medicine; CTO Board Member</p> <p><b>A Critical Need to Support Patient Centricity in Clinical Research</b></p> <ul style="list-style-type: none"> <li>• Kenneth A. Getz, Director, Sponsored Research Programs, Tufts Center for the Study of Drug Development; Chairman and Founder, The Center for Information and Study on Clinical Research Participation</li> </ul> <p><b>Community Engagement as the Human Infrastructure of Clinical Trials</b></p> <ul style="list-style-type: none"> <li>• James V. Lavery, Research Scientist in the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael’s Hospital; Associate Professor, Dalla Lana School of Public Health and Joint Centre for Bioethics, University of Toronto</li> </ul> <p><b>Optimizing Lay Representation in Health Research</b></p> <ul style="list-style-type: none"> <li>• Karen Arts, Director of Business Development, High Impact Clinical Trials Program, OICR; Board Chair, N2; Director of External Initiatives, 3CTN</li> </ul> <p><b>Successful Model of Consumer-led Community Engagement - “Power to the People”</b></p> <ul style="list-style-type: none"> <li>• Dawn Richards, Vice-President, Canadian Arthritis Patient Alliance</li> </ul> <p><b>N2 - A Shared Space to Raise Clinical Research Literacy</b>  <b>Pulling Together the Framework to Enhance Engagement in Clinical Trials</b></p> <ul style="list-style-type: none"> <li>• Linda Bennett, Executive Director, Canadian Rheumatology Research Consortium</li> </ul>
4:45pm - 5:00 pm	Closing Remarks